Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Home > Coronavirus > Cytokine Release Syndrome

Cytokine Release Syndrome

Cytokines are small proteins produced in the body to mediate cell signaling and regulation of the immune system. Cytokine Release Syndrome is characterized by an immune over-response, where the majority of the damage done to the host is due to an attack by the immune system rather than a direct cytotoxic effect by the pathogen. This systemic inflammatory response is mediated by the release (by immune cells) of inflammatory cytokines such as IFN-alpha, IFN-gamma, IL-1, IL-1 beta, IL-2, IL-2R, IL-6, IL-8, IL-10, IL-12, IL-17D, IL-18, IL-33, TNF-alpha, TGF-beta, and chemokines such as CCL2, CCL3, CCL5, CXCL8, CXCL9, and CXCL10. The overproduction of inflammatory cytokines leads to an attack on multiple organ systems resulting in ARDS, multi-organ failure, and hypotensive shock (Li, X., 2020; Huang, C., 2020). Both severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) cause a severe and highly lethal respiratory disease in humans. These diseases are also characterized by a prominent pro-inflammatory response and mediated by release of cytokines (Chan, J.F., 2015).

Cytokine Release Syndrome

Cytokine Release Syndrome Targets

Interleukin-1 Alpha (IL-1A)

IL-1A is a pro-inflammatory cytokine and an important mediator of local and systemic inflammation. Excessive IL-1A release during viral infections can cause lung and tissue inflammation, fever, and fibrosis. IL-1A suppression has been found to be effective in many inflammatory diseases, including rheumatoid arthritis.

All IL-1A Products

Interleukin-1 Beta (IL-1B)

IL-1B is a potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, it induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. It promotes differentiation of the TH17 subset of T-cells.

All IL-1B Products

Interleukin-2 (IL-2)

Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and many other activities crucial to regulation of the immune response. It can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells.

All IL-2 Products

Interleukin-2 Receptor (IL-2R)

The increased expression of IL-2R and IL-6 in serum is expected to predict increased severity of COVID-19 pneumonia and a poorer patient prognosis (Chen, L., 2020).

All IL-2R Products

Interleukin-2 Receptor Gamma (IL-2RG)

IL-2RG is a common subunit for the receptors for a variety of interleukins. Probably in association with IL-15RA, it is involved in the stimulation of neutrophil phagocytosis by IL-15.

All IL-2RG Products

Interleukin-6 (IL-6)

IL-6 is a cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response, plays an essential role in the final differentiation of B-cells into immunoglobulin-secreting cells, and is involved in lymphocyte and monocyte differentiation. IL-6 acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells, and cells of the central nervous system (CNS). It is also required for the generation of TH17 cells.

Increased expression of IL-2R, D-Dimer, and IL-6 in serum was associated with increased severity of 2019-nCoV pneumonia and poorer patient prognosis (Russell, B., 2020) (Chen, L., 2020).

All IL-6 Products

Interleukin-8 (IL-8)

IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. IL-8 is released from several cell types in response to an inflammatory stimulus.

All IL-8 Products

Interleukin-10 (IL-10)

IL-10 inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF, and GM-CSF. IL-10 is produced by activated macrophages and by helper T-cells.

All IL-10 Products

Interleukin-17D (IL-17D)

IL-17D induces expression of IL-6, CXCL8/IL-8, and CSF2/GM-CSF from endothelial cells.

All IL-17D Products

Interleukin-17A (IL-17A)

IL-17A is part of the ligand for IL-17RA and IL-17RC. The heterodimer formed by IL-17A and IL-17F is the ligand for the heterodimeric complex formed by IL-17RA and IL-17RC. It is involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines.

All IL-17A Products

Interleukin-18 (IL-18)

IL-18 augments natural killer cell activity in spleen cells and stimulates interferon gamma production in T-helper type I (TH1) cells. IL-18 belongs to the IL-1 family.

All IL-18 Products

Interferon Gamma Receptor 1 (IFNGR1)

IFNGR1 associates with IFNGR2 to form the receptor for interferon gamma (IFNG). Ligand binding stimulates activation of the JAK/STAT signaling pathway.

All IFNGR1 Products

Tyrosine-Protein Kinase JAK2

JAK2 is a non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation, and histone modification. The JAK2 pathway mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, JAK2 plays a pivotal role in signal transduction via its association with type I receptors, such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), and thrombopoietin (TPOR); or with type II receptors, including IFN-alpha, IFN-beta, IFN-gamma, and multiple interleukins. JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation, which may lead to the hypertension observed in some COVID-19 patients (Guilluy C, 2010).

All JAK2 Products

NACHT, LRR and PYD domains-containing protein 3(NLRP3)

As the sensor component of the NLRP3 inflammasome, NLRP3 plays a crucial role in innate immunity and inflammation. The SARS-CoV open reading frame 3a (ORF3a) accessory protein activates the NLRP3 inflammasome by promoting TNF receptor-associated factor 3 (TRAF3)-mediated ubiquitination of apoptosis-associated speck-like protein, containing a caspase recruitment domain (ASC). Since the ORF3a domain in SARS-CoV-2 is approximately 73% similar to SARS-CoV, it is likely to be involved in a similar mechanism (Siu, K.L., 2019).

All NLRP3 Products

Tumor Necrosis Factor-alpha (TNFa)

The TNF family of receptors and cytokines is very large and this family is frequently targeted by drugs. TNFa is a pro-inflammatory cytokine involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. TNFa inhibitors act by suppressing the physiologic response to TNFa. Inhibition of TNFa can be achieved with a monoclonal antibody, such as infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi), or with a receptor fusion protein, etanercept (Enbrel). Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19 (Russell B., 2020).

All TNFa Products

C-C motif chemokine 2 (MCP1/CCL2)

C-C motif chemokine 2 (MCP1/CCL2) is a chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. CCL2 augments monocyte anti-tumor activity, and has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates like psoriasis, rheumatoid arthritis, and atherosclerosis.

All MCP1/CCL2 Products

Granulocyte Colony-Stimulating Factor (MIP1A/GCSF)

Granulocyte/macrophage colony-stimulating factors are cytokines that act during hematopoiesis by controlling the production, differentiation, and function of granulocytes, monocytes, and macrophages. GCSF induces granulocytes and belongs to the IL-6 superfamily.

All MIP1A/GCSF Products

References
  • Chan, J. F., Lau, S. K., To, K. K., Cheng, V. C., Woo, P. C., & Yuen, K. Y. (2015). Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiology Reviews, 28(2), 465–522.
  • Chen, L., Liu, H. G., Liu, W., Liu, J., Liu, K., Shang, J., Deng, Y., & Wei, S. (2020). Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases, 43(0), E005. Advance online publication.
  • Guilluy, C., Brégeon, J., Toumaniantz, G., Rolli-Derkinderen, M., Retailleau, K., Loufrani, L., Henrion, D., Scalbert, E., Bril, A., Torres, R. M., Offermanns, S., Pacaud, P., & Loirand, G. (2010). The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nature Medicine, 16(2), 183–190
  • Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England), 395(10223), 497–506.
  • Russell, B., Moss, C., George, G., Santaolalla, A., Cope, A., Papa, S., & Van Hemelrijck, M. (2020). Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience, 14, 1022.
  • Siu, K. L., Yuen, K. S., Castaño-Rodriguez, C., Ye, Z. W., Yeung, M. L., Fung, S. Y., Yuan, S., Chan, C. P., Yuen, K. Y., Enjuanes, L., & Jin, D. Y. (2019). Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB journal: Official Publication of the Federation of American Societies for Experimental Biology, 33(8), 8865–8877.

All Cytokine Release Syndrome Products


☰ Filters
Proteins (941)
Native (1)
Over-Expression Cell Culture Supernatant (7)
Over-Expression Lysate (53)
Recombinant (870)
CCL2 / MCP1 (48)
CCL3 / MIP-1-Alpha (40)
CD119 / IFNGR1 (15)
CSF3 / G-CSF (44)
CXCL10 / IP-10 (36)
IFN Gamma / Interferon Gamma (82)
IL-10 (70)
IL17 (12)
IL17A (40)
IL18 (36)
IL1A / IL-1 Alpha (50)
IL-1B / IL-1 Beta (80)
IL2 (76)
IL2RA / CD25 (27)
IL2RB / CD122 (22)
IL2RG / CD132 (20)
IL6 / Interleukin 6 (76)
IL8 / Interleukin 8 (57)
NALP3 / NLRP3 (11)
TNF Alpha (99)
Bind (9)
ELISA (7)
Func (7)
SDS-PAGE (25)
Product Group
Coronavirus Antibodies Proteins cDNAs (940)
Cytokine Release Syndrome (941)
Cytokine Release Syndrome Proteins (940)
Animal-free (19)
No (940)
Yes (1)
10His, C-terminus (2)
10His, N-terminus (3)
10His, N-terminus + Myc, C-terminus (2)
10His-SUMO, N-terminus + Myc, C-terminus (1)
6His, C-terminus (36)
6His, N-terminus (36)
6His, N-terminus + 6His, C-terminus (1)
6His-B2M, N-terminus (2)
6His-SUMO, N-terminus (5)
7His, C-terminus (1)
8His, N-terminus (1)
DDK (Flag) (1)
DDK (Flag)-Human ACRP30headless aa 16-108 (1)
DDK,N-terminus (1)
Fc (4)
Fc, C-terminus (13)
Fc/6His,C-terminus (2)
Fc-6His, C-terminus (2)
GST (26)
GST, N-terminus (14)
GST, N-terminus + His, C-terminus (1)
His (126)
His, C-Terminal (3)
His, N-Terminal (66)
His,C-terminus (20)
His,N-terminus (5)
His-DDK (Flag), N-terminus (1)
His-Fc (1)
His-GST (13)
His-GST, N-terminus (5)
His-S (9)
His-SUMO (1)
His-T7 (48)
His-T7, N-terminus (1)
Human IgG Fc, C-terminus (2)
Human IgG1 Fc (4)
Human IgG1 Fc, C-terminus (2)
Human IgG1 Fc, N-terminus (1)
Human IgG2 Fc (2)
Human IgG4 Fc, N-terminus (1)
Human Mutant IgG1 Fc (4)
Human Mutant IgG1 Fc, N-terminus (1)
Mouse IgG1 Fc (1)
Mouse IgG2 Fc (2)
Mouse Mutant IgG2a Fc (3)
Myc-DDK (Flag) (62)
TRX-6His, N-terminus (1)
Bovine (25)
Chicken (12)
Cow (1)
Dog (27)
Goat (1)
Guinea pig (9)
Hamster-Chinese (1)
Horse (9)
Human (452)
Marmoset (1)
Monkey (1)
Monkey-Rhesus (1)
Mouse (200)
Pig (34)
Rabbit (25)
Rat (74)
Rhesus monkey (21)
Sheep (15)
Woodchuck (4)
Zebrafish (2)
293F Cells (23)
293T Cells (23)
Baculovirus (6)
CHO Cells (35)
E. coli (551)
Eukaryotic cells (1)
HEK 293 Cells (99)
Human (10)
Human Cells (37)
Insect Cells (3)
Mammalian Cells (36)
Mouse (1)
NS1 Cells (3)
Wheat Germ Extract (27)
Yeast (57)
Purified (324)
Supernatant (4)
Low endotoxin level (423)
Biologically active (266)
Animal-free (19)
IFN Gamma / Interferon Gamma Protein - Recombinant Interferon Gamma By SDS-PAGE
Select
E. coli
His,N-terminus
18.4 kDa
10 µg/$288; 50 µg/$487; 100 µg/$780; 200 µg/$972; 1 mg/$2,109; 500 µg/$1,636; 5 mg/$3,403; 2 mg/$2,298
IFN Gamma / Interferon Gamma Protein
Select
E. coli
None
Less than 1.0 EU/µg protein (determined by LAL method).
16.9kDa
100 µg/$317; 500 µg/$526; 20 µg/$245; 50 µg/$273; 250 µg/$429
Select
E. coli
None
Biologically active
Less than 0.01 ng/µg of protein (Less than 0.1 EU/µg).
20 µg/$282; 100 µg/$369
IFN Gamma / Interferon Gamma Protein - Eukaryotic Interferon Gamma (IFNg) by SDS-PAGE
Select
293F Cells
His, N-Terminal
22-27kDa
10 µg/$331; 50 µg/$752; 200 µg/$1,365; 100 µg/$1,156; 1 mg/$2,648; 500 µg/$2,144; 5 mg/$5,251; 2 mg/$2,838
IFN Gamma / Interferon Gamma Protein - Recombinant Interferon Gamma By SDS-PAGE
Select
E. coli
His
18.3 kDa
10 µg/$259; 50 µg/$331; 100 µg/$482; 200 µg/$602; 1 mg/$1,553; 500 µg/$1,156; 5 mg/$2,481; 2 mg/$1,723
IFN Gamma / Interferon Gamma Protein - Recombinant Rabbit interferon gamma detected using Goat anti Rabbit interferon gamma as the capture reagent and Goat anti Rabbit interferon gamma:Biotin as the detection reagent followed by Streptavidin:HRP.
Select
Yeast
None
16.9 kDa
5 µg/$390
IFN Gamma / Interferon Gamma Protein - Recombinant  Interferon Gamma By SDS-PAGE
Select
E. coli
His-T7
20.7 kDa
10 µg/$287; 50 µg/$482; 100 µg/$770; 200 µg/$962; 1 mg/$2,094; 500 µg/$1,623; 5 mg/$3,361; 2 mg/$2,284
IFN Gamma / Interferon Gamma Protein
Select
E. coli
None
Biologically active
16.8 kDa
10 µg/$282; 500 µg/$946; 100 µg/$468
Select
E. coli
None
Biologically active
Less than 0.01 ng/µg of protein (Less than 0.1 EU/µg).
20 µg/$281; 100 µg/$369
IFN Gamma / Interferon Gamma Protein - Recombinant Interferon Gamma By SDS-PAGE
Select
E. coli
His
18.7 kDa
10 µg/$292; 50 µg/$512; 100 µg/$817; 200 µg/$1,018; 1 mg/$2,168; 500 µg/$1,690; 5 mg/$3,571; 2 mg/$2,359
IFN Gamma / Interferon Gamma Protein - N.A.
Select
E. coli
None
Less than 1.0 EU/µg protein (determined by LAL method).
~17 kDa
100 µg/$291; 1 mg/$746
Select
E. coli
His,C-terminus
Less than 0.1 EU/µg protein (determined by LAL method).
~17 kDa (SDS-PAGE)
10 µg/$288; 50 µg/$428
IFN Gamma / Interferon Gamma Protein - Eukaryotic Interferon Gamma (IFNg) by SDS-PAGE
Select
293F Cells
His, N-Terminal
22/25kDa
10 µg/$318; 50 µg/$672; 200 µg/$1,256; 100 µg/$1,057; 1 mg/$2,507; 500 µg/$2,007; 5 mg/$4,691; 2 mg/$2,699
IFN Gamma / Interferon Gamma Protein - Recombinant Dog Interferon gamma detected using Rabbit anti Dog interferon gamma as the capture reagent and Rabbit anti Dog Interferon gamma:Biotin as the detection reagent followed by Streptavidin:HRP.
Select
Yeast
None
16.7 kDa
5 µg/$390
IFN Gamma / Interferon Gamma Protein - Recombinant Pig Interferon gamma detected using Rabbit anti Pig interferon gamma as the capture reagent and Rabbit anti Pig Interferon gamma:Biotin as the detection reagent followed by Streptavidin:HRP.
Select
Yeast
None
16.8 kDa
5 µg/$390
Select
E. coli
None
Biologically active
Less than 0.01 ng/µg (Less than 0.1 EU/µg) (determined by LAL method).
The 134 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 15,652 Da. The DTT-reduced and non-reduced protein migrate at approximately 13 kD by SDS-PAGE.
10 µg/$246; 25 µg/$283; 100 µg/$359; 500 µg/$749
Select
E. coli
None
Biologically active
Less than 0.01 ng/µg (Less than 0.1 EU/µg) (determined by LAL method).
The 144 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 16,907 Da. The DTT-reduced protein and the non-reduced protein migrate at approximately 17 kDa by SDS-PAGE.
10 µg/$264; 25 µg/$306; 100 µg/$359; 500 µg/$749
IFN Gamma / Interferon Gamma Protein - Active Interferon Gamma (IFNg) by WB
Select
E. coli
His, N-Terminal
18kDa
10 µg/$352; 50 µg/$877; 200 µg/$1,523; 100 µg/$1,298; 1 mg/$2,838; 500 µg/$2,334; 5 mg/$6,125; 2 mg/$3,268
Select
CHO Cells
None
Less than 1.0 EU/µg protein (determined by LAL method).
16.7 kDa
20 µg/$287; 100 µg/$390
Select
HEK 293 Cells
Fc, C-terminus
Less than 1.0 EU/µg protein (determined by LAL method).
42.5 kDa
100 µg/$661
Select
Mammalian Cells
None
Less than 1.0 EU/µg protein (determined by LAL method).
16.8 kDa
10 µg/$248; 50 µg/$317
Select
CHO Cells
None
Biologically active
Less than 1.0 EU/µg protein (determined by LAL method).
100 µg/$325; 1 mg/$1,195; 20 µg/$255
IFN Gamma / Interferon Gamma Protein
Select
E. coli
His, N-Terminal
16.7 kDa
50 µg/$419
Select
E. coli
His
21 kD
20 µg/$405; 1 mg/$1,679; 100 µg/$598
IFN Gamma / Interferon Gamma Protein - 12.5% SDS-PAGE of human IFNG stained with Coomassie Blue
Select
Wheat Germ Extract
GST
43.89 kDa
2 µg/$439
Viewing 1-25 of 941 product results